Do Olive and Fish Oils of the Mediterranean Diet Have a Role in Triple Negative Breast Cancer Prevention and Therapy? An Exploration of Evidence in Cells and Animal Models

Micah G. Donovan 1, Ornella I. Selmin 2,3, Barbara J. Stillwater 4, Leigh A. Neumayer 4 and Donato F. Romagnolo 2,3*

1 Interdisciplinary Cancer Biology Graduate Program, The University of Arizona, Tucson, AZ, United States, 2 University of Arizona Cancer Center, The University of Arizona, Tucson, AZ, United States, 3 Department of Nutritional Sciences, The University of Arizona, Tucson, AZ, United States, 4 Department of Surgery, Breast Surgery Oncology, The University of Arizona, Tucson, AZ, United States

Breast cancer is the most common malignancy and cause of cancer-related mortality among women worldwide. Triple negative breast cancers (TNBC) are the most aggressive and lethal of the breast cancer molecular subtypes, due in part to a poor understanding of TNBC etiology and lack of targeted therapeutics. Despite advances in the clinical management of TNBC, optimal treatment regimens remain elusive. Thus, identifying interventional approaches that suppress the initiation and progression of TNBC, while minimizing side effects, would be of great interest. Studies have documented an inverse relationship between the incidence of hormone receptor negative breast cancer and adherence to a Mediterranean Diet, particularly higher consumption of fish and olive oil.

Here, we performed a review of studies over the last 5 years investigating the effects of fish oil, olive oil and their components in model systems of TNBC. We included studies that focused on the fish oil ω-3 essential fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in addition to olive oil polyphenolic compounds and oleic acid. Both beneficial and deleterious effects on TNBC model systems are reviewed and we highlight how multiple components of these Mediterranean Diet oils target signaling pathways known to be aberrant in TNBC including PI3K/Akt/mTOR, NF-κB/COX2 and Wnt/β-catenin.

Keywords: mediterranean diet, omega 3 fatty acids, mono saturated fatty acid, triple negative breast cancer, olive and fish oil

INTRODUCTION

Breast cancer is the most common malignancy and cause of cancer-related mortality among women worldwide (1). Triple negative breast cancer (TNBC) refers to a heterogeneous subclassification of breast tumors that by definition lack expression of the estrogen receptor (ER)α, progesterone receptor (PR) and human epidermal growth factor receptor (HER)2. These tumors account for
~15% of breast cancer cases and are more likely to occur in women that are young, obese (2), from African-American or Hispanic descent (3), or harbor germline BRCA1 mutations (4). Triple negative breast cancers carry a worse prognosis than hormone receptor-positive (luminal A and luminal B) and HER2-enriched (HER2+) breast tumors (5). For TNBC, the 5y survival rate for stage I patients is ≥85% compared with ≥99 and ≥94% for luminal (A and B) and HER2+ breast cancer, respectively. Whereas, in the metastatic setting, the median survival for TNBC is ~10–13 mo compared to ~5 y for non-TNBC.

Poor prognosis of TNBC is due in part to an incomplete understanding of its molecular etiology and thus reliance on non-targeted chemotherapy for treatment. Moreover, compared with the other molecular subtypes of breast cancer, TNBC have an increased tendency for visceral and central nervous system metastases (6, 7) and carry a higher risk of relapse and distant recurrence (8, 9). Optimal chemotherapy regimens for TNBC remain elusive, although some benefit has been observed in clinical trials with neoadjuvant platinum-based therapeutics and adjuvant use of paclitaxel (2). Poly (ADP-ribose) polymerase (PARP) inhibitors have also shown promise against metastatic BRCA-mutated HER2-negative breast tumors (10). Despite these advances, the development of interventional approaches that suppress the initiation and progression of TNBC and have minimal side effects would be of great benefit.

Diet is implicated as a non-genetic risk effector in breast cancer etiology that can have both beneficial and deleterious influences (11). Moreover, cancer prevention by dietary bioactive components is of great interest as these compounds are cost effective and safe in addition to having anti-tumorigenic properties (12). The Mediterranean Diet (MD) describes the dietary patterns of cultures that have surrounded the Mediterranean sea for millennia (13). There is no absolute definition of what constitutes a MD, however it is generally accepted to be a diet that (1) is rich in plant-based foods (i.e., vegetables, fruit, whole grains, legumes, etc.); (2) uses olive oil as the principle fat source; (3) has low intakes of red and processed meat, saturated fat, and refined sugars; (4) advocates low-to-moderate intake of low-fat dairy and moderate consumption of fish; and (5) emphasizes moderate intake of alcohol (mostly red wine) with meals (14). Several scoring systems have been derived in order to quantitate MD adherence in the context of studying health outcomes (15–17) (Table 1). Adherence to the MD has been demonstrated to be inversely associated with multiple health maladies including cardiovascular disease (18), diabetes (19), Alzheimer’s disease (20), and cancer (21).

With respect to breast cancer, both clinical trials (22) and epidemiological studies (23, 24) have suggested a protective influence of MD adherence (Table 2). The PREDIMED study was a multicenter randomized primary prevention trial comparing the effect of following a MD against a low-fat diet (control) on breast cancer incidence in women (n = 4,282, 60–80 y) at high cardiovascular disease risk (22). In fully adjusted models, a group adhering to a MD rich in extra virgin olive oil (EVOO) had significantly less overall breast cancer cases compared with the control group (HR = 0.32, 95%CI: 0.13–0.79). Meta-analyses investigating the association between MD adherence and BC incidence have reported either modest changes in risk ratio (RR = 0.93–0.86) (23, 24) or no significant associations (25, 26). However, of the latter studies, one (26) found significant risk reductions for ER- tumors (RR = 0.84) upon subgroup stratification, whereas no associations were found for total breast cancer or ER+ breast cancer.

To date, no meta-analysis has investigated the association between MD adherence and TNBC incidence specifically. However, individual observational studies (i.e., not meta-analyses) suggest a potential inverse relationship (Table 2). A cohort study using data from the Netherlands Cancer Registry and the Dutch Pathology Registry reported an inverse association between higher adherence to the alternate Mediterranean Diet Score (aMED) and incidence of ER- breast cancer. Less significant inverse associations were also found for PR- and ER-/PR-tumors. However, no associations were found for ER+, PR+ or ER+/PR+ tumors (26). In a subgroup analysis of data from the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) study, authors found adherence to the adapted relative Mediterranean diet (arMED) index was associated with decreased odds of ER-/PR- tumors in post-menopausal women (17). A case-control study using cases from the Spanish GEICAM Breast Cancer Research Group reported lower odds of TNBC incidence with adherence to both an “a priori” and “a posteriori” MD pattern (27). A more recent case-control study in the Spanish population did not find a statistical significance (P-trend = 0.322) in the lower odds ratio calculated for TNBC incidence, however authors suggested this was likely due to a small number of cases (n = 76) (28). A study investigating the relationship in population of U.S. women with a family history of breast cancer (n = 33)

### Table 1 | Scoring systems used to quantitate MD adherence, derived from (15–17).

| Scoring system                        | Components                                                                 | Scoring                                                                 |
|---------------------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------|
| Mediterranean Diet Score (MDS)        | Alcohol, cereals, dairy*, fish, fruits and nuts, legumes, meat and meat products*, MUFA:SFA ratio, vegetables | Range 0–9: One point for intake ≥ study-specific median of components without* One point for intake ≤ study-specific median of components with* One point for alcohol intake of 5–25 g/day for women and 10–50 g/day for men (otherwise 0) |
| Alternate Mediterranean Diet Score (arMED) | Alcohol, fish, fruit, legumes, MUFA:SFA, nuts, red and processed meat*, vegetables, whole grains | Range 0–9: One point for intake ≥ study-specific median of components without* One point for intake ≤ study-specific median of components with* One point for alcohol intake of 5–15 g/d |
| Adapted Relative Mediterranean Diet Score (arMED) | fruits, vegetables, legumes, fish, olive oil, cereals, dairy*, meat products* | Range 0–16: 0–2 points assigned to country-specific tertiles of intake for components without* Scoring inverted for components with* |

MUFA, monounsaturated fatty acids; SFA, saturated fatty acids.

---

Donovan et al. Mediterranean Diet and Breast Cancer

TABLE 1 | Scoring systems used to quantitate MD adherence, derived from (15–17).

| Scoring system                        | Components                                                                 | Scoring                                                                 |
|---------------------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------|
| Mediterranean Diet Score (MDS)        | Alcohol, cereals, dairy*, fish, fruits and nuts, legumes, meat and meat products*, MUFA:SFA ratio, vegetables | Range 0–9: One point for intake ≥ study-specific median of components without* One point for intake ≤ study-specific median of components with* One point for alcohol intake of 5–25 g/day for women and 10–50 g/day for men (otherwise 0) |
| Alternate Mediterranean Diet Score (arMED) | Alcohol, fish, fruit, legumes, MUFA:SFA, nuts, red and processed meat*, vegetables, whole grains | Range 0–9: One point for intake ≥ study-specific median of components without* One point for intake ≤ study-specific median of components with* One point for alcohol intake of 5–15 g/d |
| Adapted Relative Mediterranean Diet Score (arMED) | fruits, vegetables, legumes, fish, olive oil, cereals, dairy*, meat products* | Range 0–16: 0–2 points assigned to country-specific tertiles of intake for components without* Scoring inverted for components with* |

MUFA, monounsaturated fatty acids; SFA, saturated fatty acids.
suggested higher MD adherence trended toward a risk reduction of 34%, although the trend was not statistically significant (p = 0.07), perhaps due to small sample size (29).

With respect to mortality, one study has reported an inverse relationship between following a MD and non-BC related death (RR = 0.39), although no association was found for breast cancer-specific mortality (30). To our knowledge, no studies have investigated specifically the effect of MD adherence on TNBC mortality. However, given the observation that the MD has a more distinct relationship with hormone receptor-negative breast tumor incidence, the capacity to detect an effect of MD adherence on TNBC outcomes may be lost in non-stratified analyses of breast cancer cases. Results from the PREDIMED trial and subgroup analyses in epidemiological studies implicate the protective effect of the MD against breast cancer incidence is attributable in part to higher intakes of olive oil and fish/fish oil (31–33). Moreover, preclinical studies have documented protective effects of both olive (34–36) and fish oil (37–39) in rodent mammary tumor models. Given the inverse association between higher consumption of fish and olive oil and breast cancer incidence, the purpose of this article was to review studies that investigated the effects of olive oil, fish oil and their components on model systems of TNBC.

### METHODS

We performed a traditional review of studies over the last 5 years (Figure 1) investigating the effects of fish oil, olive oil

### TABLE 2 | Effect of MD adherence on BC incidence reported from studies in human populations.

| Study design | Intervention/variable | Outcome | Effect/association | HR/OR/RR (95% CI) | References |
|--------------|-----------------------|---------|-------------------|-------------------|------------|
| Clinical trials | MD supplemented with EVOO | BC incidence | Decreased | HR = 0.32 (0.13–0.79) | (22) |
| Meta-analyses | MD adherence | BC incidence | Inverse | RR = 0.93 (0.87–0.99) | (23) |
| | MD adherence | BC incidence | Inverse | RR = 0.92 (0.87–0.96) | (24) |
| | MD adherence | BC incidence | N/A | RR = 0.96 (0.90–1.03) | (25) |
| | MD adherence | BC incidence | N/A | RR = 0.94 (0.87–1.01) | (26) |
| | ER+ BC incidence | N/A | Inverse | RR = 0.92 (0.85–1.01) | (28) |
| | ER- BC incidence | N/A | Inverse | RR = 0.84 (0.73–0.97) | (28) |
| Observational | aMED adherence | BC incidence | N/A | HR = 0.87 (0.72–1.08) | (26) |
| | aMED adherence | ER+ BC incidence | N/A | HR = 0.87 (0.69–1.10) | (26) |
| | aMED adherence | PR+ BC incidence | N/A | HR = 0.90 (0.69–1.19) | (26) |
| | aMED adherence | ER/PR+ BC incidence | N/A | HR = 0.91 (0.69–1.21) | (26) |
| | aMED adherence | ER- BC incidence | Inverse | HR = 0.60 (0.39–0.93) | (23) |
| | aMED adherence | PR- BC incidence | Inverse | HR = 0.72 (0.52–1.05) | (23) |
| | aMED adherence | ER/PR- BC incidence | Inverse | HR = 0.61 (0.35–1.01) | (23) |
| | aMED adherence | BC incidence | Inverse | HR = 0.93 (0.87, 0.99) | (17) |
| | aMED adherence | ER/PR+ BC incidence | N/A | HR = 0.92 (0.85, 1.00) | (17) |
| | aMED adherence | ER/PR- BC incidence | N/A | HR = 0.84 (0.69, 1.02) | (17) |
| | aMED adherence | P.M. BC incidence | Inverse | HR = 0.93 (0.87, 0.99) | (17) |
| | aMED adherence | P.M. ER/PR+ BC incidence | N/A | HR = 0.92 (0.85, 1.01) | (17) |
| | aMED adherence | P.M. ER/PR- BC incidence | Inverse | HR = 0.80 (0.65, 0.99) | (17) |
| | aMED adherence | Pr.M BC incidence | N/A | HR = 0.97 (0.81, 1.15) | (27) |
| | aMED adherence | Pr.M. ER/PR+ BC incidence | N/A | HR = 0.86 (0.66, 1.13) | (27) |
| | aMED adherence | Pr.M. ER/PR- BC incidence | N/A | HR = 1.09 (0.66, 1.82) | (27) |
| | “a posteriori” MD adherence | ER/PR+ , HER2- BC incidence | N/A | OR = 0.91 (0.82–1.01) | (27) |
| | “a posteriori” MD adherence | HER2+ BC incidence | N/A | OR = 0.94 (0.80–1.11) | (27) |
| | “a posteriori” MD adherence | TNBC BC incidence | Inverse | OR = 0.80 (0.65–0.99) | (27) |
| | “a posteriori” MD adherence | ER/PR+, HER2- BC incidence | Inverse | OR = 0.83 (0.73–0.94) | (27) |
| | “a posteriori” MD adherence | HER2+ BC incidence | N/A | OR = 0.86 (0.71–1.04) | (27) |
| | “a posteriori” MD adherence | TNBC BC incidence | Inverse | OR = 0.63 (0.50–0.78) | (27) |
| | aMED adherence | ER/PR+ | N/A | OR = 0.91 (0.67–1.23) | (28) |
| | aMED adherence | HER2+ | N/A | OR = 0.86 (0.51–1.47) | (28) |
| | aMED adherence | TNBC incidence | N/A | OR = 0.73 (0.34–1.55) | (28) |
| | aMED adherence | BC incidence | Inverse | HR = 0.89 (0.76–1.06) | (29) |
| | aMED adherence | ER/PR+ BC incidence | N/A | HR = 0.87 (0.72–1.07) | (29) |
| | aMED adherence | ER/PR- BC incidence | N/A | HR = 0.80 (0.50–1.29) | (29) |
| | aMED adherence | TNBC incidence | N/A | HR = 0.66 (0.37–1.19) | (29) |

**a** Significant P-trend reported in bold.

**b** Characterized by high intakes of fish, vegetables, legumes, boiled potatoes, fruits, olives and vegetable oil, and a low intake of juices.

aMED, alternate Mediterranean Diet Score; arMED, adapted relative Mediterranean diet.
FIGURE 1 | Methodology for review of effects of fish oil, olive oil, and their components on model systems of TNBC in studies published within the last 5 y. We searched PubMed with the search queries “(fish oil AND triple negative breast cancer) OR (fish oil AND TNBC) OR (DHA AND triple negative breast cancer) OR (DHA AND TNBC) OR (EPA AND triple negative breast cancer) OR (EPA AND TNBC)” and “(olive oil AND triple negative breast cancer) OR (olive oil AND TNBC) OR (oleic acid AND triple negative breast cancer) OR (oleic acid AND TNBC).” We also searched with the terms “fish oil” and “olive oil” in combination with the names of the 27 most commonly cited TNBC cell lines (separate searches).

and their components in model systems of TNBC. Searches of the PubMed database with the queries “(fish oil AND triple negative breast cancer) OR (fish oil AND TNBC) OR (DHA AND triple negative breast cancer) OR (DHA AND TNBC) OR (EPA AND triple negative breast cancer) OR (EPA AND TNBC)” and “(olive oil AND triple negative breast cancer) OR (olive oil AND TNBC) OR (oleic acid AND triple negative breast cancer) OR (oleic acid AND TNBC).” We also searched with the terms “fish oil” and “olive oil” in combination with the names of the 27 most commonly cited TNBC cell lines (separate searches).

FISH OIL AND TNBC: REVIEW
Effects on Proliferation and Growth
The tumor suppressive effects of fish oil ω-3 essential fatty acids on TNBC cells are summarized in Figure 2. Several studies documented anti-proliferative effects of both DHA and EPA in preclinical models of TNBC (41–46). Some suggest the effect of DHA may be stronger than that of EPA (41, 44). For example, in MDA-MB-231 TNBC cells, DHA treatment for 24 h decreased cell viability at a range of concentrations starting at 5 µM (20% growth inhibition) up to 50 µM (85% growth inhibition) (41). On the other hand, EPA did not produce a significant reduction until 25 µM (~15% growth inhibition) and only 60% growth inhibition was observed at the highest dose (50 µM). Both compounds had a slight anti-proliferative effect in T47D luminal breast cancer cells, however the maximal effect was only ~40% growth inhibition by DHA at 50 µM. Another study reported the 24 h half maximal inhibitory concentration (IC₅₀) for cell viability was ~130 µM for DHA and ~160 µM for EPA in MDA-MB-231 cells, and ~120 µM for DHA and ~180 µM for EPA in MCF7 luminal breast cancer cells (44). On the other hand, EPA and DHA seemed to have similar anti-proliferative efficacy in a study that documented an ~25% decrease in the number of
MCF7 (luminal A), SK-BR-3 (HER2+), MDA-MB-231 (TNBC) and HCC1806 (TNBC) cells treated with either EPA or DHA (80 µM) for 72 h (42). Notably, 160 µM of either compound decreased MDA-MB-231 cell count by ~75% and approached 100% cytotoxic efficiency against the HCC1806 cell line.

Treatment of MDA-MB-231 cells with DHA (10–25 µM) lead to an accumulation of the subG1 cell population with concomitant increases in PARP cleavage and caspase-3 activity (41). Moreover, flow cytometry analysis of Annexin V and propidium iodide (PI) staining indicated DHA promoted apoptotic cell death in both MDA-MB-231 and HCC1806 TNBC cells (42). Interestingly, one study found co-treatment with vitamin D3 enhanced the pro-apoptotic effect of both EPA and DHA in MCF7, SK-BR-3, and MDA-MB-231 cells (46).

In addition to apoptosis, one study (43) showed DHA may also trigger TNBC cell death through induction of pyroptosis, a cell death program distinct from apoptosis that is triggered by inflammatory signaling and mediated by inflammasomes (76). Here, DHA treatment had a cytotoxic effect on MDA-MB-231 cells with a half maximal effective concentration (EC50) of 101.6 µM (43). Intriguingly, DHA treatment had no effect on the viability of non-malignant MCF10A mammary cells or peripheral blood mononuclear cells. Pyroptosis is initiated by activation of Caspase-1, which proteolytically cleaves interleukin (IL)-1β and gasdermin D (GSDMD) to their active forms (77, 78). The latter molecule, GSDMD, forms membrane pores, which ultimately triggers pyroptotic cell death. Indeed, MDA-MB-231 cells treated with DHA had higher levels of activated Caspase-1 and GSDMD, enhanced IL-1β secretion, and other markers of pyroptotic cell death (43).

Changes in TNBC cell proliferation and growth resultant from DHA treatment may also be related to modulation of cell metabolism and bioenergetics. Treatment with DHA dose-dependently decreased both glycolytic and mitochondrial metabolism in both BT-474 and MDA-MB-231 TNBC cells, however no effect was observed in the non-malignant MCF10A cell line (47). These specific effects in the TNBC cells were linked to DHA-mediated decreases in hypoxia-inducible factor 1 (HIF1α), a key regulator of glycolytic metabolism and the Warburg effect in cancer cells (79). Moreover, in TNBC cells, DHA decreased HIF1α transcriptional activity and expression of its targets glucose transporter 1 (GLUT 1) and lactate dehydrogenase (LDH), which are key mediators of glycolytic metabolism in cancer cells (47).

A greater anti-proliferative effect on MDA-MB-231 cells was observed with the endocannabinoid derivatives of DHA and EPA, docosahexaenoyl-ethanolamine (DHEA) and eicosapentaenoyl-ethanolamine (EPEA), compared to the parent compounds (44). In these experiments the IC50 for cell viability was ~130 µM for DHA after both 24 and 48 h; ~80 µM and ~130 µM for DHEA at 24 and 48 h, respectively; ~160 µM for EPA after 24 and 48 h; and ~80 µM and ~50 µM for EPEA at 24 and 48 h respectively. Changes in proliferation induced by the ω-3 compounds were shown to be regulated by the endocannabinoid receptors CB1 and CB2. Co-treating cells with an antagonist specific to CB1 decreased the anti-proliferative effect of DHA and EPEA and completely ablated the effects of DHEA, but increased EPA efficacy. On the other hand, a CB2-specific antagonist increased the efficacy of DHA and DHEA but decreased the effect of EPA and EPEA. The effect of DHA and DHEA was also increased by antagonizing both CB1 and CB2 in co-treatment experiments, whereas dual antagonism attenuated the efficacy of EPA and EPEA. Of note, this study also documented that none of the compounds tested had an effect on viability of the non-malignant MCF10A cell line.

There may be cell-specific and metabolite-specific effects of DHA on BC cell proliferation. For example, treatment with DHA (100 µM for 96 h) significantly decreased MDA-MB-231 TNBC cell proliferation by ~85% compared to controls, whereas no statistically significant effect was observed in BT-549 TNBC cells (45). On the other hand, 4-OXO-DHA, an oxidized DHA metabolite, had a more potent anti-proliferative effect in MDA-MB-231 cells and decreased BT-549 proliferation by ~85% compared to control cells. In luminal breast cancer cells, DHA and 4-OXO-DHA increased MCF7 cell proliferation, whereas both metabolites decreased proliferation of T47D and SK-BR-3 cells. Interestingly, this study suggests different BC subtypes, and even different tumors of the same subtype, may have differential responses to DHA. However, other studies showed DHA and EPA had similar IC50 values against cell viability in both MCF7 and MDA-MB-231 cells (44).

Gene expression analyses have been used to stratify TNBC into multiple subtypes. For example, Lehmann et al. have proposed four TNBC tumor specific subtypes referred to as basal like (BL1), BL2, mesenchymal and luminal androgen receptor (LAR) (80). Basal-like tumors that are triple negative and have low expression of luminal differentiation markers, high expression of genes involved with the epithelial-to-mesenchymal transition (EMT) and immune response, and are enriched with cancer stem cells are referred to as claudin-low (CL) TNBC (81). One study demonstrated supplementation with
EPA+DHA (0.025%) significantly decreased growth of models of both Claudin low (CL) and basal-like (BL) murine mammary tumors in mice fed an obesogenic diet (60% fat) (48). Mice were orthotopically injected with BL or CL cells derived from murine MMTV-Wnt-1 tumors. Compared with mice fed only the obesogenic diet, mice that received the EPA+DHA supplement had significantly less tumor area and weight. Analysis of tumors showed the EPA+DHA supplement increased the level of cleaved caspase-3 compared to controls and attenuated upregulation of inflammation markers such as cyclooxygenase-2 (COX2) and phospho-p65, the major subunit for NF-kB (48).

In Fat-1 mice, the tumor volume orthotopic EO771 cell xenografts was decreased by ~80%, which was associated with decreased NF-kB binding affinity, compared to wildtype (WT) controls (41). Fat-1 carry a transgene for Caenorhabditis elegans ω3 desaturase (fat-1 gene), which causes them to produce high amounts of endogenous ω-3 polyunsaturated fatty acids (PUFA) from endogenous ω-6 PUFA. The effect of DHA on tumor NF-kB activity was corroborated by cell culture experiments using MDA-MB-231 cells (41). Treatment of MDA-MB-231 cells with DHA (0–50 μM) dose-dependently decreased cell viability, which was associated with an accumulation of the subG1 cell population and concomitant increases in PARP cleavage and caspase-3 activity. These effects were attributed in part to DHA-induced decreases in the expression of COX2 and VEGF and promoter activity of NF-kB.

**Effects on Migration, Invasion and Metastasis**

Compared with the other BC subtypes, TNBC have an increased propensity for visceral and central nervous system metastases (6, 7). The epithelial-to-mesenchymal transition (EMT) is a process whereby epithelial cells lose polarity and cell-cell contacts and increase migratory capacities, which facilitates movement into surrounding tissue (invasion) and seeding in distant locations (82). Several studies have documented suppressive effects of fish oil ω-3 fatty acids on EMT characteristics including cell migration and invasion, which are key to the metastatic process. Transforming growth factor (TGF)β is a cytokine that promotes EMT of epithelial cells (82). In two different TNBC cell lines, MDA-MB-435 and Hs578T, DHA (25 μM) suppressed transforming growth factor (TGF)β-mediated increases in the expression of the EMT mediators gremlin (GREM)1, N-cadherin, vimentin, and Slug (49). Stimulation of MDA-MB-435 cells with TGFβ had a pro-migratory effect in wound healing assays that was attenuated by either GREM1 silencing or treatment with DHA. Authors attributed the effect of DHA in part to inhibition of ERK phosphorylation.

Treatment with DHA (100 μM for 24 h) also decreased invasion of MDA-MB-231 cells in Boyden chamber assays by 60% compared to control cells (50). These effects were abrogated upon co-treatment with siRNA against keratin, type II cytoskeletal 1 (KRT1), which was significantly upregulated upon treatment with DHA alone. Downregulation of KRT1 has been shown to occur as human mammary epithelial cells undergo malignant transformation mediated by retroviral addition of Simian Virus 40 Early Region (SV40 ER), exogenous human telomerase reverse transcriptase (hTERT), and an activated, oncogenic form of hRAS (hRAS-V12) (83).

The EMT has been shown to be triggered by a variety of factors including Wnt/β-catenin (84), fascin-1 (85), and STAT3 (86) among others. The interaction of WNT ligands with their receptors leads to stabilization and nuclear translocation of β-catenin, a transcription factor regulating genes involved in proliferation, differentiation/development, and migration (87). Silencing fascin-1 suppresses EMT in part through preventing nuclear localization of β-catenin (85). On the other hand, STAT3 promotes EMT through upregulation of Twist-1 (86). The Hs578T cell line is a highly migratory model of TNBC that expresses high levels of fascin-1, β-catenin and STAT3α (51). Treatment of Hs578T cells with DHA (100 μM for 24 h) significantly decreased their migration in wound healing assays, which was linked to a dose-dependent decrease in fascin-1, β-catenin and STAT3α expression. Pretreatment with DHA was also shown to suppress 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced increases in MCF7 cell migration, Wnt-1 protein levels and secretion, and β-catenin expression.

Hypoxia in the tumor microenvironment is associated with an increased risk for metastasis and mortality (88). The cellular response to hypoxia is largely regulated by the activity of the HIF1α and HIF2 transcription factors. Targets of the HIF transcription factors include genes involved in several aspects of the EMT and metastasis including matrix metalloproteinase (MMP)2, MMP9, vimentin, and snail 1 and 2 among many others (89). Matrix metalloproteinas facilitate invasion by promoting the degradation of the extracellular matrix and basement membrane (88). On the other hand, vimentin is an intermediate filament protein that promotes cell migration through regulation of microtubules and actomyosin networks (90). Vimentin expression is considered an EMT marker and is associated with poor prognosis in multiple cancer types (91). Under both normoxic and hypoxic conditions, DHA (100 μM) decreased migration of MDA-MB-231 cells in wound healing assays (52). This was shown to be associated with increased miR-194 expression and decreased miR-106b, which led to downregulation of vimentin, matrix metalloproteinase (MMP)2, and MMP9 and increased talin2. Talins are cytoskeletal proteins that link integrin adhesion proteins with F-actin in cells (92) and have significant roles in cell migration and invasion.

Integrins are transmembrane heterodimeric proteins that are formed through combinations of α and β subunits (95). Integrins act as signaling molecules and transducers of mechanical stimuli and have significant roles in cell migration and invasion. Targeting β-containing integrins (e.g., α5β3) has shown promise in preclinical studies to reverse EMT and reduce migration and invasion of MDA-MB-231 and BT549 TNBC cells (96). Brown et al. used transwell assays in both the absence and presence
of a synthetic basement membrane matrix to assess changes in MDA-MB-231 cell migration and invasion, respectively (44). Compared to controls, only DHA lowered migratory capacity (∼70%), however both DHA and EPA decreased invasion by ∼70 and ∼55%, respectively. Western blotting showed DHA treatment of MDA-MB-231 cells decreased protein levels of the β3 integrin subunit, matrix MMP1 and VEGF, whereas EPA only affected levels of β3 integrin (44). It has been shown that metastatic TNBC cells have higher expression of MMP1, MMP9, MMP13, and vascular endothelial growth factor (VEGF) among several other factors involved in EMT (97). While the function of MMP proteins is to degrade the extracellular matrix, VEGF is a permeability factor that promotes angiogenesis and cancer cell intravasation (89). Activity of VEGF is also needed for lymphatic migration of tumor cells (97).

Sites of TNBC metastatic seeding include the viscera and central nervous system rather than the bone, which is common in ER-positive breast cancer. Gene expression analyses of cells from BC brain metastases demonstrated COX2 as a key facilitator of cancer cell entry passed the blood-brain-barrier (98). Moreover, high tumor expression of COX2 is associated with worse 5 y survival in TNBC patients (99). A study in the MDA-MB-231 cell line documented 10 µM treatment with DHA produced an ∼10-fold decrease in invasion through Matrigel chambers, which was associated with downregulation of MMP2 and MMP9 expression and COX2 promoter activity (41). Treatment with DHA was also shown to attenuate the dose-dependent induction of MMP2 and MMP9 mediated by either prostaglandin E2 or arachidonic acid. Authors also demonstrated NF-κB signaling was suppressed by DHA treatment. Higher activity of NF-κB has been observed in TNBC cells (100) and has been shown to promote invasion and metastasis (101). Given the effect of DHA on MMP2, MMP9, COX2, and NF-κB, authors studied its impact on metastasis by injecting EO771 murine BC cells into the tail veins of wildtype (WT) and Fat-1 mice (41). Experimental metastasis was significantly decreased in Fat-1 mice compared with WT littermates, which was associated with decreased levels of the endothelial marker CD31.

Effects on Therapeutic Response

Multiple studies suggested addition of fish oil ω-3 fatty acids may enhance the therapeutic response of TNBC to standard chemotherapeutics. Docetaxel is a taxane used as a first line therapy in TNBC (102). In MDA-MB-231 cells, DHA (30 µM) enhanced the cytotoxic efficacy of docetaxel (53). Moreover, treatment with DHA prevented docetaxel-induced increases in membrane localization of PKCe and PKCδ and phosphorylation of ERK1/2 and Akt, which are associated with drug resistance (53). Dietary supplementation with fish oil (5% by weight) was also shown to enhance the therapeutic response of N-methylnitrosourea (NMU)-induced tumors to docetaxel in rats, which was attributed to downregulation of ERK- and Akt-regulated survival pathways. Another study documented addition of DHA to the diet (3.4%) of two different patient-derived TNBC xenograft (PDX) mouse models significantly improved the efficacy of docetaxel (54). Here, authors used the MAXF574 PDX, which is poorly differentiated and well-vascularized and the MAXF401 model, which is moderately differentiated and poorly vascularized. In mice bearing the MAXF574 PDX and treated with docetaxel, dietary DHA resulted in a 64% reduction in tumor weight compared to control-fed mice. Similarly, tumor weight was decreased by 34% in DHA-fed mice bearing the MAXF401 PDX treated with docetaxel compared with control-fed animals. In both PDX models, decreased in tumor volume were attributed to higher expression of the pro-apoptotic factors Ripk1 and Bid; lower expression of the Bcl-2, PARP, and surviving; and induction of cell-cycle arrest.

Doxorubicin is another first-line chemotherapy used in TNBC (103). Studies showed DHA enhanced the efficacy of doxorubicin in TNBC cells and an in vivo mouse model (55). Single agent treatment with either doxorubicin or DHA (60 µM) decreased MDA-MB-231 cell viability. Compared to control treatment with only doxorubicin, treatment with DHA and doxorubicin had a stronger effect on cell viability and brought about cell cycle arrest. These changes were attributed to increased expression of several pro-apoptotic factors, including caspase-10 and caspase-9, and decreased levels of cell-cycle progression proteins, including cyclin B1 and WEE1, in DHA-treated cells.

Apatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR)2, which has been shown to be upregulated in TNBC patients (104). Addition of apatinib to the treatment regimen of metastatic TNBC patients provided a beneficial outcome in two case reports (105, 106). In MDA-MB-231 cells, single-agent treatment with either apatinib or DHA dose-dependently decreased proliferation (56). On the other hand, treatment with different combinations of apatinib + DHA formulations showed improved efficacy. The optimal dose was found to be 40.5 µM of apatinib (75% of the single-agent IC50) in combination with 112.5 µM DHA (75% of single-agent IC50). Authors reported these effects were due in part to downregulation of Bcl-2 and phosphorylated Akt and increased levels of cleaved caspase-3 and BAX (56). Together, these studies demonstrate a potential efficacy for adjuvant DHA in TNBC treatment regimens.

OLIVE OIL AND TNBC: REVIEW

Hydroxytyrosol and Oleuropein on Proliferation, Migration and Invasion

The effects of olive oil components on TNBC cells are summarized in Table 3. Hydroxytyrosol is a simple phenol found in olive oil at concentrations ranging from 0.71 to 2.7 mg/kg (112). Previous studies had highlighted an anti-tumorigenic potential of hydroxytyrosol due to its capacity to protect against oxidative DNA damage in non-malignant MCF10A breast cells (113). More recently, hydroxytyrosol was shown to have inhibitory effects on breast cancer stem cell (BCSC) self-renewal in a comprehensive investigation using multiple TNBC cell lines (57). Tumor enrichment of BCSC has been suggested to play a role in the aggressiveness and poor prognosis associated with TNBC (114). Hydroxytyrosol at a range of concentrations (0.5–100 µM) suppressed mammosphere-forming efficiency, a marker
of BCSC self-renewal, of the TNBC cell lines SUM159PT, BT549, MDA-MB-231, and Hs578T (57). In fact, the 0.5 \( \mu \)M dose was sufficient to suppress mammosphere formation of SUM159PT cells by 40% and the three other TNBC cell lines (BT549, MDA-MB-231, and Hs578T) by 50% after 72 h in culture. Interestingly, treatment with hydroxytyrosol actually increased the size of Hs578T spheres, despite decreasing formation (58). Interestingly, treatment with hydroxytyrosol actually increased the size of Hs578T spheres, despite decreasing formation (58).

### Oleanolic Acid on Proliferation and Migration

Oleanolic acid is a triterpenoid abundant in olive oil (26.71–50.13 \( \mu \)g) (75) with previous studies (>5 years prior to this review) that had demonstrated anti-proliferative capacity in both MDA-MB-231 TNBC and MCF7 luminal A BC cells with respective half maximal inhibitory concentrations (IC50) of 7.0 and 7.5 \( \mu \)M (107). These anti-proliferative effects were attributed to induced cell cycle arrest and apoptosis in these cell lines. Since then, multiple derivatives of oleanolic acid have been investigated for their anti-BC potential. Methyl 3-hydroxyimino-11-oxoolean-12-en-28-oate, a synthetic derivative, reduced MDA-MB-231 cell viability with an IC50 of 21.08 \( \mu \)M by activating apoptotic (extrinsic) and autophagic pathways (60). Another oleanolic acid derivative, SZC017, was shown to inhibit cell viability of both MDA-MB-231 (IC50 = 28.09 \( \mu \)M) and MCF7 (IC50 = 26.47 \( \mu \)M) (61). Unfortunately, authors used only the MCF7 cell line to investigate the mechanisms underlying these effects, which were attributed to apoptotic and autophagic induction in part by decreasing Akt activation and nuclear accumulation of phosphorylated-p65.

This report is somewhat contrasted by another study which demonstrated a cytotoxic effect of oleanolic acid in MDA-MB-231 cells but not MCF7 cells (62). After 24 h in media containing 100 \( \mu \)M oleanolic acid, only 68% of MDA-MB-231 cells survived, whereas there was no statistical decrease in the number of MCF7 cells. However, these differences could be due to the fact that a much higher dose (100 \( \mu \)M) was used in these experiments. In the ER-negative non-malignant MCF10A cell line, oleanolic acid had a cytotoxic effect at both 10 \( \mu \)M (83% cell survival) and 100 \( \mu \)M (13% cell survival) after 24 h in culture. Oleanolic acid was also shown to inhibit proliferation in a dose-dependent manner after 24, 48, and 72 h in culture and the decrease in proliferation was significant starting...
at 1 µM. Similar effects were observed in the MCF10A cells starting at the 10 µM dose, however an anti-proliferative effect was only observed in the MCF7 cells at 100 µM. The anti-proliferative effect in MDA-MB-231 cells was ascribed in part to intracellular accumulation of ROS. Interestingly, oleic acid also protected against H₂O₂-induced DNA damage in MCF10A cells (62).

In addition to anti-proliferative effects, oleanic acid may also have anti migratory potential in TNBC cells. Treating MDA-MB-231 cells with oleic acid suppressed cell migration with an IC₅₀ of 14.0 µM (63). Moreover, carbamoylation of oleanoic acid to derive 3-O-[N-(30-chlorobenzenesulfonyl)]-carbamoyl]-oleanolic acid (IC₅₀ = 2.1 µM) and 3-O-[N-(50-fluorobenzenesulfonyl)-carbamoyl]-oleanolic acid (IC₅₀ = 1.4 µM) provided more potent antimigratory effects. Western blot analysis indicated the antimigratory effects of oleanic acid and its derivatives were linked to inhibition of the breast tumor kinase (BRK)/Paxillin/Ras-related C3 botulinum toxin substrate (Rac1) signaling pathway.

**Oleic Acid on Proliferation, Migration and Therapeutic Response**

Oleic acid is the most abundant free fatty acid in olive oil (809.53–1045.52 µg/g) followed by palmitic acid (285.41–362.95 µg/g) (75). Previous studies had documented oleic acid may have a pro-tumorigenic effect on TNBC. For example, in MDA-MB-231 TNBC cells, oleic acid increased proliferation via PI3K activation (108), invasion via (MMP9) secretion (109) and migration through increased production of arachidonic acid and subsequent activation of focal adhesion kinase (FAK) (110). A recent study demonstrated a 4-fold increase in MDA-MB-231 cell migration by oleic acid (100 µM) was attenuated by concurrent treatment with selective inhibitors for free fatty acid receptor (FFAR)1 and FFAR4, suggesting their involvement in mediating the pro-migratory effect of oleic acid in TNBC cells (64). Selective inhibitors of PI3K and AKT also attenuated oleic acid-induced migration of these cells and subsequent experiments revealed this was due to oleic acid-induced phosphorylation of both AKT1 and AKT2. The increase in migration elicited by oleic acid was demonstrated to require AKT2 expression in MDA-MB-231 cells.

Oleic acid also increased the activity of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a transcription factor that regulates genes involved in invasion, in MDA-MB-231 cells. In summary, this study documented critical roles of FFAR, PI3K, AKT, and NF-κB in mediating the pro-invasion/migration effect of oleic acid on TNBC cells.

Cancer-associated fibroblasts have been shown to promote EMT characteristics and increase migration of MDA-MB-231 and MCF7 BC cells in culture (115). However, this effect is attenuated by knockdown of stearoyl-CoA desaturase (SCD1), a endoplasmic reticulum desaturase that regulates membrane fluidity via conversion of saturated fatty acids to MUFA (116). Interestingly, treatment of SCD1-knockdown MDA-MB-231 and MCF7 cells with oleic acid restored CAF-mediated pro-migratory effects in wound-healing assays (65). High expression of SCD1 in TNBC was associated with increased proportion of metastasis-related deaths (HR = 6.73) (66). In wound-healing assays, oleic acid treatment increased wound recovery of MDA-MB-231 and luminal A (T47D and MCF7) by 1.5-fold compared with untreated cells (66). However, wound recovery by oleic acid-stimulated MDA-MB-231 cells was attributed to enhanced migration, whereas luminal A cell recovery was due to proliferation. An analysis of migratory dynamics revealed oleic acid increased the speed and changed the directionality of MDA-MB-231 cell migration. These changes were linked to oleic acid-mediated activation of a phospholipase D (PLD)/mTOR signaling pathway. In line with this, treating MDA-MB-231 with rapamycin attenuated oleic acid-induced (250 µM) proliferation, invasion and migration (67). This was accredited to inhibitory effects of oleic acid and activating effects of rapamycin on autophagy in MDA-MB-231 cells.

Cisplatin is a platinum-based chemotherapy that demonstrated efficacy as a first-line chemotherapy in TNBC patients (117). However, multiple mechanisms of cisplatin-resistance have been identified in TNBC cells (118). Despite the potential deleterious effects of oleic acid on TNBC cells, one study demonstrated a potential synergistic relationship between oleate and Cisplatin on inducing apoptosis in MDA-MB-231 cells (68). Treatment with oleate (50 µM) increased the number of cells undergoing apoptosis when used in combination with Cisplatin compared to cells treated with Cisplatin alone, which was attributed to oleic acid-dependent downregulation of fatty acid synthase (FASN). Previous studies had also demonstrated oleic acid enhanced the sensitivity of MDA-MB-231 TNBC cells and T47D and MCF7 luminal A cells to the cytotoxic effects of paclitaxel (119). Although it has not been tested, there may be a potential role for oleic acid in modulating TNBC therapeutic response.

**Oleocanthal on Proliferation, Migration and Invasion**

Oleocanthal is a secoiridoid present in olive oil that was previously shown to inhibit proliferation (20 µM), migration (10 µM), and invasion (10 µM) of MDA-MB-231 TNBC cells in vitro (111). These effects were attributed to suppression of MET proto-oncogene, receptor tyrosine kinase (c-Met) signaling, a pro-carcinogenic factor upregulated in ~43% of TNBC samples (120). A follow up study demonstrated oleocanthal had a pro-apoptotic effect in these cells and stabilized a more epithelial, rather than mesenchymal, phenotype (69). In mice, (-)-oleocanthal (5 mg/kg) administered via intraperitoneal injection (3X/week) reduced MDA-MB-231 triple-negative xenograft tumor volume by 60% compared to vehicle-treated controls. These in vivo outcomes at this dose were attributed to inhibition of c-MET and cytostatic effects rather than a pro-apoptotic influence. Interestingly, the tumor suppressive effects of oleocanthal may be selective to malignant cells. For example, one study showed that (-)-oleocanthal (10-20 µM over 24-72 h) decreased cell viability, proliferation and migration of MDA-MB-231 TNBC cells and MCF7 luminal A BC cells in culture, but had no effect on non-malignant MCF10A cells (70). These differences in effect were linked to downregulation of the Ca²⁺
channel transient receptor potential cation channel subfamily C member 6 (TRPC6), which is overexpressed by the BC cell lines. Previous studies showed silencing TRPC6 decreased proliferation and migration of MDA-MB-231 cells (121).

Another study tested the effect of oral oleocanthal exposure on a xenograft model of breast tumor recurrence (71). These experiments demonstrated the capacity of oral oleocanthal (10 mg/kg daily) to reduce the growth of recurrent MDA-MB-231 xenograft tumors by 58%, which was associated with lower serum levels of cancer antigen (CA)15-3 (71), a tumor marker of post-operative recurrence and metastasis risk (122). Tumors from oleocanthal-treated mice also had decreased phosphorylated c-MET, increased in E-cadherin and downregulation of vimentin (71). A taste-masked oleocanthal formulation using (+)-xylitol as an inert carrier was developed to improve palatability of oral oleocanthal administration (72). Daily oral administration of this formulation (10 mg/kg) to athymic nude mice starting 45 days before orthotopic inoculation of MDA-MB-231 cells decreased mean tumor volume by 49% compared with control mice. This same dose (10 mg/kg) was also shown to decrease MDA-MB-231 tumor volume by 48% when administered to mice 5 days after xenograft inoculation. Mice that received this xylitol-oleocanthal formula after surgical resection of MDA-MB-231 tumors also had extended recurrence-free survival, 60% recurrence prevention, and significantly decreased volume of recurring tumors compared with placebo-treated mice. Again, inhibitory effects on tumor growth were attributed to antagonism toward c-MET.

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays a significant role in cell survival, growth and proliferation. Activity of mTOR is increased via multiple mitogenic signals, namely phosphatidylinositol 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) signaling (123). As is the case for most cancers, aberrations in the PI3K/AKT/mTOR pathway are common in TNBC (124). Molecular modeling studies documented oleocanthal shared with a dual inhibitor of mTOR and PI3K, 9/10 critical binding interactions with mTOR and in vitro kinase assays found the IC50 for oleocanthal against mTOR activity to be 708 nM (73). In cell culture studies, oleocanthal had strong anti-proliferative effects in MDA-MB-231 TNBC cells (IC50 = 18.5 µM) and T47D (IC50 = 20.0 µM) and MCF7 (28.0 µM) luminal A cells. Western blotting revealed these effects were linked with decreased phosphorylation (activation) of mTOR in MDA-MB-231 cells treated with oleocanthal.

**Pinoresinol on Proliferation**

Pinoresinol is a lignan found in olive oil (0.07–0.9 mg/kg) (125) that is considered a phytoestrogen due to its similar chemical structure to estrogen. Previous studies had demonstrated pinoresinol (100 µM) had anti-proliferative effects on MDA-MB-231 cells (70 ± 6% cell survival) but not MCF7 cells (96 ± 7% cell survival) (126). Recently, pinoresinol treatment was shown to have cytotoxic effects on MDA-MB-231 cells at concentrations ranging from 0.001–100 µM, whereas only low levels (0.001–0.01 µM) were cytotoxic to MCF7 cells (74). Interestingly, the cytotoxic effect of pinoresinol may be specific to tumorigenic cells. This was evidenced by the fact that none of the treatment doses (0.001–0.01 µM) led to >10% cell death in the non-malignant MCF10A cell line. Moreover, the amount of MCF10A cell death with the 0.001 and 0.01 µM pinoresinol treatment was statistically lower than that of MDA-MB-231 and MCF7 cells at those doses. Further investigation revealed an anti-proliferative effect of pinoresinol in the BC cell lines that was associated with a pro-oxidant effect. On the other hand, in the non-tumorigenic cell line pinoresinol had an antioxidant effect, which reduced cellular oxidative stress and H2O2-induced DNA damage.

**DISCUSSION**

Triple negative breast cancers are the most aggressive and lethal of the BC molecular subtypes. Although there have been advances in chemotherapeutic regimens for TNBC (2), there is a potential benefit to identifying lifestyle interventions that target molecular effectors of TNBC initiation and progression. The diet is a key example of a modifiable risk effector that influences a myriad of molecular processes with both positive and negative implications toward mammmary tumorigenesis. In both clinical trial (22) and meta-analysis (21, 23, 24), adherence to the MD has been shown to be inversely associated with BC development. Stratified analyses in observational studies identified this relationship to be a more distinct for ER-negative breast cancers in particular (26). Although no meta-analysis has specifically analyzed MD adherence and TNBC incidence, individual observational studies have reported an inverse relationship (27). With this in mind, we sought to review the recent evidence regarding an effect of two principle components of the MD, fish and olive oil, on model systems of TNBC to gain perspective on the role of a MD to aid in TNBC prevention and prognosis.

Components of both fish and olive oil demonstrated antagonistic effects toward several cancer hallmarks in TNBC cells. Both ω-3 essential fatty acids of fish oil, DHA and EPA, had anti-proliferative effects against two different TNBC cell lines, MDA-MB-231 and HCC1806, in cell culture experiments (42). Moreover, in mice, a diet supplemented with EPA and DHA suppressed tumorigenesis of two different mouse-derived TNBC xenograft tumor models (48). Several components of olive oil were also shown to have anti-proliferative effects against TNBC cells including hydroxytyrosol, oleuropein (58), oleanolic acid (107), oleocanthal (111), and pinoresinol (74). Oleocanthal, also inhibited TNBC cell invasion in cell culture experiments (111) and suppressed the formation of primary (69) and recurrent (71) MDA-MB-231 xenograft tumor formation when administered to mice.

Cell proliferation and viability can be decreased through multiple mechanisms including induction of cell death programs (e.g., apoptosis and pyroptosis), suppression of upregulated growth signaling and cell-cycle arrest. Both DHA and EPA were shown to activate apoptosis (42) and DHA activated pyroptosis (43) and modulated cellular energetics (47) in TNBC cells. The anti-proliferative effects of oleuropein (59), oleanolic acid (107), and oleocanthal (69) were also linked to apoptotic induction. On the other hand, hydroxytyrosol and its ester oleuropein were suggested to activate autophagy (58). An attractive aspect of
the anti-proliferative effect of several of the components of the MD oils including DHA (43, 44), EPA (44), oleocanthal (70), and pinoresinol (74, 125), is their apparent selectivity toward malignant cells. In these experiments that documented inhibitory effects of these compounds on proliferation of TNBC cells, no effect was observed in the non-malignant MCF10A cell line. It is important to note, the vast majority of studies we reviewed did not include non-malignant control cell lines in their experiments, so one could expect more than just the aforementioned bioactives (DHA, EPA, oleocanthal, pinoresinol) elicit this selective effect.

Activating the EMT and progressing through the metastatic process is a key determinant of BC prognosis as the median survival rate for metastatic TNBC is ~10–13 mo (5). In addition to proliferation, DHA was shown to inhibit migration (44, 49, 51, 52) and invasion (41, 44, 50) of TNBC in culture. Mouse experiments using the tail vein injection model in Fat-1 mice, which produce higher amounts of endogenous ω-3 essential fatty acids, also suggested a potential anti-metastatic effect (41). However, these experiments did not use a human derived TNBC cell line nor an exogenous source of ω-3, which would more resemble exposure to a MD pattern. The olive oil polyphenol hydroxytyrosol also produced an anti-migratory effect in SUM159PT, BT549, and MDA-MB-231 TNBC cells and in this same study decreased BCSC self-renewal in 3D mammospheres (57). Both hydroxytyrosol and its ester oleuropein also inhibited MDA-MB-231 cell invasion (58). An anti-migratory effect was also produced by treating MDA-MB-231 cells with oleanolic acid (63) and oleocanthal (111). Oleocanthal was also anti-invasive against MDA-MB-231 cells (111).

Despite these potential benefits, we would be remiss to not discuss the deleterious effects observed with treatment of TNBC cells with oleic acid, the principle fatty acid in olive oil. The evidence reviewed here suggests oleic acid alone may increase TNBC cell proliferation (108), migration (110), and invasion (109). However, in the context of the MD, oleic acid exposure would occur along with a cocktail of several other dietary components that may abrogate its negative effect. Studies showed inhibitors of PI3K, AKT, and mTOR attenuated oleic acid-induced increases in TNBC cell proliferation, migration, and invasion (64, 67) and the MD oils alone contain several components that antagonize the PI3K/AKT/mTOR signaling pathway. For example, oleocanthal was shown to be an inhibitor of both PI3K and mTOR (73) and both DHA (94) and oleanolic acid (61) inhibited AKT. Thus, there is a strong potential that the pro-tumorigenic effect of oleic acid on TNBC is blunted when delivered as complete olive oil or in the context of a MD.

Aberrations in the PI3K/AKT/mTOR signaling are common in TNBC (Reviewed here (135)). Activation of the canonical Wnt signaling pathway stabilizes the transcription factor β-catenin, which leads to its accumulation and subsequent nuclear translocation (136). β-catenin controls multiple genes involved in regulating cell proliferation, differentiation/development, and migration (87). Upregulated Wnt/β-catenin confers increased migratory capacity, colony formation, stemness, and chemoresistance of TNBC cells in cell culture and tumor formation of TNBC xenografts in mouse models (137). Interestingly, studies of BC patients have shown nuclear accumulation of β-catenin in tumors is associated with the TNBC phenotype (138) and upregulated Wnt/β-catenin predicts poor prognosis for TNBC (139). In two studies, DHA had suppressive effects on Wnt/β-catenin-mediated tumorigenicity. Mice fed a diet enriched with EPA+DHA (0.025%) showed a decreased tumor burden from MMTV-Wnt-1 xenografts compared to control-fed littermates (48). In cell culture experiments, DHA dose-dependently decreased expression of β-catenin in Hs578T TNBC cells and attenuated TPA-induced increases in Wnt-1 levels and secretion and β-catenin expression in MCF7 cells (51). On the other hand, the olive oil phenol hydroxytyrosol suppressed BCSC renewal and mammosphere formation in BT549 and MDA-MB-231 in part through inhibition of Wnt/β-catenin signaling.

A perplexing question that emerges when examining epidemiological studies investigating the association between MD adherence and BC incidence is: why is there a distinct relationship for ER-negative breast cancers in particular? For
example, a meta-analysis suggested the risks for ER- (RR = 0.60), PR- (RR = 0.72), and ER-/PR- (RR = 0.61) BC were significantly decreased with higher adherence to a MD, whereas no associations were found for ER+, PR+, or ER+/PR+ tumors (26). This could be explained in part by the fact that some of the studies we reviewed demonstrated several MD compounds imparted differential effects on proliferation of TNBC cells compared to non-TNBC cells. For example, at 50 µM, DHA produced 85% growth inhibition of MDA-MB-231 TNBC cells compared to only 40% inhibition of T47D luminal breast cancer cell growth (41). Another study actually documented a pro-proliferative effect of DHA in MCF7 luminal cells (45). The olive oil compound oleuropein was shown to have a stronger anti-proliferative effect against MDA-MB-231 cells (IC50 = 36.2 µM) compared to MCF7 cells (95.4 µM) (59). Whereas, oleanolic acid treatment was cytotoxic against MDA-MB-231 cells but had no...
effect on MCF7 cell proliferation (62). The MDA-MB-231 cell line was also more sensitive than MCF7 cells to the cytotoxic effects of pinoresinol (74). Studies have demonstrated both overexpression of COX2 (140) and nuclear accumulation of ω-catenin (138) are associated with the TNBC subtype. Given that MD components covered in this review showed antagonistic effects on both COX2 and ω-catenin, another explanation for an inverse relationship between MD adherence and ER-negative breast cancers could be the specific molecular targets of the MD in TNBC and HER2+ cells. The molecular effects of the MD diet and its constituents on HER2+ breast cancer was outside the scope of this review. However, there is significant evidence to suggest oleic acid and olive oil inhibit HER2+ tumorigenesis and may have therapeutic potential in these cancers [Reviewed here (141)].

Of the studies reviewed here, we identified a general lack of accountability for the heterogeneity of TNBC. As exemplified by Lehmann et al., TNBC can be clustered into several distinct subtypes, which are heterogeneous with respect to clinical parameters such as prognoses and response to therapy (80). The majority of studies we reviewed that performed cell culture experiments used only one TNBC cell line. In addition to the different effects observed between TNBC and non-TNBC treated with MD components, there may be differential outcomes for different TNBC subtypes. We highlighted an example of this with study investigating DHA (45). For MDA-MB-231 cells, 100 µM decreased proliferation by 85% compared to controls, whereas no changes were seen in BT-549 TNBC cell proliferation (45). Moreover, the HCC1806 TNBC cell line was more sensitive to DHA treatment than MDA-MB-231 cells in a different study (42). These differences could be resultant from distinct genetic and molecular features of these cell lines. For example, the MDA-MB-231 cell line has been characterized as mesenchymal stem-like, whereas BT-549 and HCC1806 are considered mesenchymal-like and basal-like 2, respectively (142). BT-549 cells have been shown to harbor a homozygous PTEN deletion, whereas both MDA-MB-231 and HCC1806 have been reported to not have aberrations in the PI3K pathway (40). On the other hand, MDA-MB-231 cells are also reported to have mutations in KRAS. Another consideration is the fact that the majority of BRCA1-mutated tumors (~70%) are TNBC (4), however the MDA-MB-231, BT-549, and HCC1806 cell lines all harbor wildtype BRCA1 genes (40). This highlights the need for studies looking to impact TNBC prevention and therapy to utilize model systems of TNBC that account for heterogeneity.

The question as to whether or not the MD deserves a role in TNBC prevention and therapy remains unclear at this time. Although we highlighted several examples of fish and olive oil components having anti-tumorigenic effects in TNBC model systems, more work needs to be done in order to optimize clinical recommendations. For starters, MD guidelines call for more specific dietary changes than just increases fish and olive oil consumption. A potentially significant contributor to the effect of MD adherence on breast cancer risk is higher consumption of vegetables and fruits. Unfortunately, a thorough review of the effects of vegetable and fruit bioactive components on TNBC model systems would have exceeded the scope of this current review. However, this is still open for investigation. Furthermore, the potential pro-tumorigenic effect oleic acid may have on TNBC cells demands a careful approach. Although we speculated of a potential entourage effect by delivering oleic acid in the context of a MD, no study has specifically tested if the pro-oncogenic outcomes of oleic acid are abrogated by other MD diet components. This too remains open for investigation.

**AUTHOR CONTRIBUTIONS**

MD, OS, BS, LN, and DR contributed to the conception and development of the manuscript. MD had primary responsibility for the writing of the manuscript. OS and DR contributed to the writing, review, and editing of the manuscript. BS and LN were responsible for the clinical content of the work, contributed to the writing, and review of the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from the US Department of Defense Breast Cancer Program (BC134119, BC142258); Cancer Biology Training Grant (T32CA009213); Arizona Cancer Center CROC Pilot Project and Support Grant (P30CA023074); and USDA-NIFA ARZT-1370460-R23-155.

**REFERENCES**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, (2012). CA Cancer J Clin. (2015) 65:87–108. doi: 10.3322/caac.21262

2. Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol. (2018) 25(Suppl.1):S142–50. doi: 10.3747/co.25.3954

3. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. (2010) 363:1938–48. doi: 10.1056/NEJMra1001389

4. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. (2010) 28:1145–53. doi: 10.1200/JCO.2009.22.4725

5. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. (2019) 321:288–300. doi: 10.1001/jama.2018.19323

6. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. (2007) 115:423–8. doi: 10.1007/s10549-008-0086-2

7. Rakha EA, Chan S. Metastatic triple-negative breast cancer. Curr Oncol. (2011) 23:587–600. doi: 10.1016/j.cron.2011.03.013

8. Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, et al. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget. (2015) 6:26560–74. doi: 10.18632/oncotarget.5306

9. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. (2007) 13:4429–34. doi: 10.1158/1078-0432.CCR-06-3045
10. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. (2017) 377:523–33. doi: 10.1056/NEJMoa1704650
11. Rossi RE, Pericelous M, Mandair D, Whyard T, Caplin ME. The role of dietary factors in prevention and progression of breast cancer. Anticancer Res. (2014) 34:6861–75.
12. Abdull Razis AF, Noor NM. Cruciferous vegetables: dietary phytochemicals for cancer prevention. Asian Pac J Cancer Prev. (2013) 14:1565–70. doi: 10.7314/APJCP.2013.14.3.1565
13. Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. (1995) 61(Suppl.):1402s–6. doi: 10.1093/ajcn/61.6.1402S
14. Donovan MG, Selmin OI, Doetschman TC, Romagnolo DF. Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. (2006) 16:559–68. doi: 10.1016/j.numecd.2005.08.006
15. Fung TT, McCullough ML, Newby PK, Manson JE, Meigs JB, Rifai N, et al. Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr. (2005) 82:163–73. doi: 10.1093/ajcn/82.1.163
16. Buckland G, Travier N, Cottet V, Gonzalez CA, Lujan-Barroso L, Agudo A, et al. Adherence to the Mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study. Int J Cancer. (2013) 132:2918–27. doi: 10.1002/ijc.27958
17. Martinez-Gonzalez MA, Bes-Rastrollo M. Dietary patterns, Mediterranean diet, and cardiovascular disease. Curr Opin Lipidol. (2014) 25:20–6. doi: 10.1097/MOL.0000000000000044
18. Schwinghschalk L, Missbach B, Konig J, Hoffmann G. Adherence to a Mediterranean diet and risk of diabetes: a systematic review and meta-analysis. Public Health Nutr. (2015) 18:1292–9. doi: 10.1017/S1368980014001542
19. Toledo E, Salas-Salvadó J, Donat-Vargas C, Buil-Cosiales P, Estruch R, Ros E, et al. Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the PREDiMeD trial: a randomized clinical trial. JAMA Intern Med. (2015) 175:1752–60. doi: 10.1001/jamainternmed.2015.4838
20. Schwinghschalk L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis of observational studies. Cancer Med. (2015) 4:1933–47. doi: 10.1002/cam4.539
21. Schwinghschalk L, Schwedhelm C, Galbete C, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis. Nutrients. (2017) 9:1063. doi: 10.3390/nu90101063
22. Bloomfield HE, Koeller E, Greer N, MacDonald R, Kane R, Wilt TJ. Effects of dietary factors in prevention and progression of breast cancer. Anticancer Res. (2014) 34:3591–92.
23. Castello A, Pollan M, Buisjes B, Ruiz A, Casas AM, Baena-Canadas JM, et al. Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpICAM study. Br J Cancer. (2014) 111:1454–62. doi: 10.1038/bjc.2014.434
24. Castello A, Boldo E, Perez-Gomez B, Lope V, Alzibar JM, Martin V, et al. Adherence to the Western, prudent and Mediterranean dietary patterns and breast cancer risk: MCC-spain study. Maturitas. (2017) 103:8–15. doi: 10.1016/j.maturitas.2017.06.020
25. Petimar J, Park YM, Smith-Warner SA, Fung TT, Sandler DP. Dietary index scores and invasive breast cancer risk among women with a family history of breast cancer. Am J Clin Nutr. (2019) 109:1393–401. doi: 10.1093/ajcn/nqy592
26. Kim EH, Willett WC, Fung T, Rosner B, Holmes MD. Diet quality indices and postmenopausal breast cancer survival. Nutr Cancer. (2011) 63:381–8. doi: 10.1080/01635581.2011.539563
27. Gallus S, Bosetti C, La Vecchia C. Mediterranean diet and cancer risk. Eur J Cancer Prev. (2004) 13:447–52. doi: 10.1097/00008469-200410000-00013
28. Wu AH, Yu MC, Tseng CC, Stanczyk FZ, Pike MC. Dietary patterns and breast cancer risk in Asian American women. Am J Clin Nutr. (2009) 89:1145–54. doi: 10.3945/ajcn.2008.26915
29. Demetrio CU, Hadjisavvas A, Loizidou MA, Loucaides G, Neophytou I, Sieri S, et al. The Mediterranean diet and breast cancer risk in greek-cypriot women: a case-control study. BMC Cancer. (2012) 12:115. doi: 10.1186/1471-2407-12-113
30. Lasekan JA, Clayton MK, Gendron-Fitzpatrick A, Ney DM. Dietary olive and safflower oils in promotion of DMBA-induced mammary tumorigenesis in rats. Nutr Cancer. (1990) 13:153–63. doi: 10.1080/01635589009514056
31. Solanas M, Hurtado A, Costa I, Morral R, Menendez JA, Colomer R, et al. Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet. Int J Oncol. (2002) 21:745–53. doi: 10.3892/ijoi.21.4.745
32. Cohen LA, Epstein M, Pittman B, Rivenson A. The influence of different varieties of olive oil on N-methyl nitrosourea (NMU)-induced mammary tumorigenesis. Anticancer Res. (2000) 20:2307–12.
33. Li J, Li K, Gao I, Guo X, Lu M, Li Z, et al. Maternal exposure to an n-3 polysaturated fatty acid diet decreases mammary cancer risk of female offspring in adulthood. Food Funct. (2018) 9:5768–77. doi: 10.1039/C8FO01006D
34. Manns S, Chakraborty T, Damodaran S, Samanta K, Rana B, Chatterjee M. Protective role of fish oil (Moxpea) on early events of rat mammary carcinogenesis by modulation of DNA-protein crosslinks, cell proliferation and p53 expression. Cancer Cell Int. (2007) 7.6. doi: 10.1186/1475-2877-6-7
35. Su HM, Hsieh PH, Chen FH. A maternal high n-6 fat diet with fish oil supplementation during pregnancy and lactation in rats decreases breast cancer risk in the female offspring. J Nutr Biochem. (2010) 21:1033–7. doi: 10.1016/j.jnutbio.2009.08.007
36. Chavez KJ, Garmella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. (2010) 32:35–48. doi: 10.3233/BD-2010-0307
37. Yun EJ, Song KS, Shin S, Kim S, Heo JY, Kweon GR, et al. Docosahexaenoic acid suppresses breast cancer cell metastasis by targeting matrix-metalloproteinases. Oncotarget. (2016) 7:19961–71. doi: 10.18632/oncotarget.10266
38. Lin G, Zhu S, Wu Y, Song C, Wang W, Zhang Y, et al. ω-3 free fatty acids and all-trans retinoic acid synergistically induce growth inhibition of three subtypes of breast cancer cell lines. Sci Rep. (2017) 7:2929. doi: 10.1038/s41598-017-03231-9
39. Pizano N, Luzete BC, Kiffer L, Corrêa LH, de Oliveira Santos I, Assumpção JAE, et al. Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells. Sci Rep. (2018) 8:1952. doi: 10.1038/s41598-018-20422-0
40. Brown I, Lee J, Sneddon AA, Cascio MG, Pertwee RG, Wahle KWJ, et al. Anticancer effects of n-3 EPA and DHA and their endocannabinoid derivatives on breast cancer cell growth and invasion. Prostaglandins Leukot Essent Fatty Acids. (2019) 156:102024. doi: 10.1016/j.plefa.2019.102024
41. Yoshida I, Kamiya K, Amin S, Gwak H, Lee BO, et al. Docosahexaenoic acid attenuates breast cancer cell metabolism and the Warburg phenotype by targeting bioenergetic function. Mol Carcinogenesis. (2015) 54:810–20. doi: 10.1002/mc.22151
48. Ford NA, Rossi EL, Barnett K, Yang P, Bowers LW, Hidaka BH, et al. Omega-3 acid ethyl esters block the proinflammatory effects of obesity in mouse models of postmenopausal basal-like and claudin-low breast cancer. *Cancer Prev Res.* (2015) 8:796–806. doi: 10.1158/1940-6207.CAPR-15-0018

49. Sung NJ, Kim NE, Bae NY, Jo HS, Park SA. DHA inhibits gremlin-1-induced epithelial-to-mesenchymal transition via ERK suppression in human breast cancer cells. *Biosci. Rep.* (2020) 40:1042.BSR20200164. doi: 10.1042/BSR20200164

50. Blancaert V, Kerviel V, Lepinay A, Joubert-Durigneux V, Honde marble H, et al. Long chain n-3 polyunsaturated fatty acids increase the efficacy of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer cell line. *Breast Cancer.* (2020) 594–606. doi: 10.1002/jcb.27738

51. Lii CK, Chang JW, Chen JJ, Chen HW, Liu KL, Yeh SL, et al. Docosahexaenoic acid inhibits 12-O-tetradecanoylphorbol-13-acetate-induced fascin-1-dependent breast cancer cell migration by suppressing the PKCα- and Wnt-1/β-catenin-mediated pathways. *Onco Targets.* (2016) 7:25162–79. doi: 10.18632/oncotarget.7301

52. Javadian M, Shekari N, Soltani-Zangbar MS, Mohammadi A, Mansoori B, Maralbashi S, et al. Docosahexaenoic acid suppresses migration of triple-negative breast cancer cell through targeting metastasis-related genes and microRNA under normoxic and hypoxic conditions. *J Cell Biochem.* (2020) 121:2416–27. doi: 10.1002/jcb.29464

53. Chauvin L, Goupille C, Blanc C, Pinault M, Domingo I, Guimaraes C, et al. Long chain n-3 polyunsaturated fatty acids increase the efficacy of docostahexaenoic acid in estrogen receptor-negative breast cancer cells by downregulating Akt and PKC epsilon/delta-induced ERK pathways. *Biochim Biophys Acta.* (2016) 1861:380–90. doi: 10.1016/j.bbalip.2016.01.012

54. Newell M, Goruk S, Mazurak V, Postovit L, Field CJ. Role of docosahexaenoic acid in enhancement of docostahexaenoic acid action in patient-derived breast cancer xenografts. *Breast Cancer Res Treat.* (2019) 177:357–67. doi: 10.1007/s10549-019-05331-8

55. Newell M, Bruin M, Field CJ. Treatment with DHA modifies the response of MDA-MB-231 breast cancer cells and tumors from nu/nu mice to doxorubicin through apoptosis and cell cycle arrest. *J Nutr.* (2019) 149:46–56. doi: 10.1093/jn/nxy224

56. Ma Y, Yu J, Li Q, Su Q, Cao B. Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapy. *Biosi Biotechnol Biochem.* (2020) 84:743–56. doi: 10.1080/10969451.2019.1709789

57. Cruz-Lozano M, Gonzalez-Gonzalez A, Marchal JA, Munoz-Muela E, Molina MP, Cara FE, et al. Hydroxytyrosol inhibits cancer stem cells and tumor growth in breast cancer models. *PLoS ONE.* (2014) 9:e97622. doi: 10.1371/journal.pone.0097622

58. Dizel-Bello R, Jardin I, Lopez JJ, El Haouari M, Aitarejos C. SCD1 activity promotes cell migration via a PLD-mTOR pathway in the MDA-MB-231 triple-negative breast cancer cell line. *Breast Cancer.* (2020) 11:637. doi: 10.3390/cancers11060637

59. Qusa M, Siddique A, Nazral S, El Sayed K. Olive oil phenolic (-)-oleocanthal (+)-xylitol-based solid dispersion formulations with potent oral anti-breast cancer activities. *Int J Pharm.* (2019) 569:18596. doi: 10.1016/j.ijpharm.2019.118596

60. Khanfar MA, Bardawel SK, Akl MR, Al Sayed KA. (-)-Oleocanthal prevents breast cancer locoregional recurrence after primary tumor surgical excision and neoadjuvant targeted therapy in orthotopic nude mouse models. *Cancers.* (2019) 11:637. doi: 10.3390/cancers11060637

61. Siddique AB, Ayoub NM, Tajmim A, Meyer SA, Hill RA, El Sayed KA. (-)-Oleocanthal inhibits pyroptosis by blocking gasdermin D pore formation. *Apoptosis.* (2016) 21:736–45. doi: 10.1038/s41590-020-0669-6

62. Lukić I, Da Ros A, Guella G, Camin F, Masuero D, Mulinacci N, et al. Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis. *Antioxidants.* (2017) 22:865–76. doi: 10.3390/antiox7040017-1366-2

63. Akl MR, Ayoub NM, Mohyeddin MM, Bussena BA, Foudah AI, Liu Y, et al. Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. *PLoS ONE.* (2014) 9:e97622. doi: 10.1371/journal.pone.0097622

64. Lukić I, Da Ros A, Guella G, Camin F, Masuero D, Mulinacci N, et al. Lipid profiling and stable isotopic data analysis for differentiation of extra virgin olive oils based on their origin. *Molecules.* (2019) 25:4. doi: 10.3390/molecules25010004

65. Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. *Immuno Rev.* (2011) 243:206–14. doi: 10.1111/j.1600-065X.2011.01342.x

66. Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Negative staining of different ovarian cancer subtypes: implications for neoadjuvant chemotherapy selection. *PLoS ONE.* (2016) 11:e0157368. doi: 10.1371/journal.pone.0157368

67. Matossian MD, Burks HE, Bowles AC, Elliott S, Hoang VT, Sabol RA, et al. A novel patient-derived xenograft model for claudin-low breast cancer.
Donovan et al. Mediterranean Diet and Breast Cancer

100. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Aparicio Saldedo ML. State of art of advanced triple negative breast cancer. Breast J. (2019) 25:967–76. doi: 10.1111/tbj.13349

101. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kappaB addiction and its role in cancer: ‘one size does not fit all’. Oncogene. (2011) 30:1615–30. doi: 10.1038/onc.2010.566

102. Chakravarti B, Maurya R, Siddiqui JA, Bid HK, Rajendran SM, Yadav PP, et al. In vitro anti-breast cancer activity of ethanolic extract of Wrightia tomentosa: role of pro-apoptotic effects of oleic acid and urosolic acid. J Ethnopharmacol. (2012) 142:72–9. doi: 10.1016/j.jep.2012.04.015

103. Hardy S, Langelier Y, Prentki M. Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Res. (2000) 60:6353–8.

104. Gao Z, Shi M, Wang Y, Chen J, Ou Y. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2. Pathol Res Pract. (2019) 215:152422. doi: 10.1016/j.prp.2019.04.014

105. Herbst A, Jurinovic V, Krebs S, Thieme SE, Blum H, Goke B, et al. Talin 2 is a large and complex gene encoding the α/β 18:533–48. doi: 10.1038/s41568-018-0038-z

106. Li T, Wang SB, Lei KJ, Jiang MQ, Jia YM. Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: a case report. Medicine. (2019) 98:e14182. doi: 10.1097/MD.0000000000014182

107. Chakravarti B, Maurya R, Siddiqui JA, Bid HK, Rajendran SM, Yadav PP, et al. In vitro anti-breast cancer activity of ethanolic extract of Wrightia tomentosa: role of pro-apoptotic effects of oleic acid and urosolic acid. J Ethnopharmacol. (2012) 142:72–9. doi: 10.1016/j.jep.2012.04.015

108. Hardy S, Langelier Y, Prentki M. Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Res. (2000) 60:6353–8.

109. Soto-Guzman A, Navarro-Tito N, Castro-Sanchez L, Martinez-Orozco R, Salazar EP. Oleic acid promotes MMP-9 secretion and invasion in breast cancer cells. Clin Exp Metast. (2010) 27:505–15. doi: 10.1007/s10585-010-9340-1

110. Navarro-Tito N, Soto-Guzman A, Castro-Sanchez L, Martinez-Orozco R, Salazar EP. Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway. Int J Biochem Cell Biol. (2010) 42:306–17. doi: 10.1016/j.biocel.2009.11.010

111. Elmagar AY, Sylvester PW, El Sayed KA. (−)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med. (2011) 77:1013–9. doi: 10.1055/s-0030-1270724

112. Miho H, Moral J, Lopez-Gonzalez MA, Diez CM, Priego-Capote F. The phenolic profile of virgin olive oil is influenced by malaxation conditions and determines the oxidative stability. Food Chem. (2020) 314:126183. doi: 10.1016/j.foodchem.2020.126183

113. Warleta F, Quessada CS, Campos M, Allouche Y, Beltran G, Gaforio J. Hydroxytyrosol protects against oxidative DNA damage in human breast cells. Hum. Nutr. (2011) 3:839–57. doi: 10.3390/nu3100839

114. Idowu MO, Kiompakos M, Demou C, Burton RS, Grimes MM, Powers CN, et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol. (2012) 43:364–73. doi: 10.1016/j.humpath.2011.05.005

115. Angelucci C, Maucci G, Colabianchi A, Iacopino F, D’Alessio A, Maiorana A, et al. Stearoyl-CoA desaturase 1 and paracrine diffusible signals have a major role in the promotion of breast cancer cell migration induced by cancer-associated fibroblasts. Br J Cancer. (2015) 112:1675–86. doi: 10.1038/bjc.2015.135

116. Zhang J, Lin Y, Sun XJ, Wang BY, Wang ZH, Luo JF, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol. (2018) 29:1369. doi: 10.1016/j.annonc.2018.07.009

117. Hill DR, Harper A, Malcolm J, McAndrews MS, Mockus SM, Patterson SE, et al. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. BMC Cancer. (2019) 19:1039. doi: 10.1186/s12885-019-2627-9
122. Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS ONE. (2015) 10:e0133830. doi: 10.1371/journal.pone.0133830

123. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham J. The PI3K pathway in human disease. Cell. (2017) 170:605–35. doi: 10.1016/j.cell.2017.07.029

124. Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. (2018) 169:397–406. doi: 10.1007/s10549-018-4697-y

125. Allouche Y, Jimenez A, Gaforio JJ, Uceda M, Beltran G. How heating affects extra virgin olive oil quality indexes and chemical composition. J Agric Food Chem. (2007) 55:9666–54. doi: 10.1021/jf070628u

126. Sepporta MV, Mazza T, Morozzi G, Fabiani R. Pinoresinol inhibits proliferation and induces differentiation on human HL60 leukemia cells. Nutr Cancer. (2013) 65:1208–18. doi: 10.1080/01635581.2013.828089

127. Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: from tumor cell signaling to clinical trials. Pharmacol Ther. (2017) 175:91–106. doi: 10.1016/j.pharmthera.2017.02.037

128. Khan MA, Jain VK, Rizwanullah M, Ahmad J, Jain K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today. (2019) 24:2181–91. doi: 10.1016/j.drudis.2019.09.001

129. Stasiopoulos I, Shah T, Penet M-F, Krishnamachary B, Bhujwalla Z. COX-2 in cancer: gordian knot or achilles heel? Front Pharmacol. (2013) 4:34. doi: 10.3389/fphar.2013.00034

130. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol. (2004) 31(Suppl.3):64–73. doi: 10.1053/j.seminoncol.2004.01.008

131. Poligone B, Baldwin AS. Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J Biol Chem. (2001) 276:38658–64. doi: 10.1074/jbc.M106599200

132. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. (2009) 1:a001651. doi: 10.1101/cshperspect.a001651